Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FibroBiologics, Inc.FBLG · Entity 7875 | Director | June 23, 2026 | June 24, 2026 |
| NUVASIVE INCNUVA · Entity 110002 | President | June 08, 2020 | June 10, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FibroBiologics, Inc.
Report date June 23, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2036-06-22 | Direct | 30,803 |
Reported balance
After 2026-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-23 · Grant · Acquired 30,803 · Balance 30,803 F1: The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting.
NUVASIVE INC
Report date June 08, 2020 · Filed June 10, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 82,595 |
Reported balance
After 2020-06-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-06-08 · Sale · Disposed 3,000 · Balance 82,595 F1: Sale effected pursuant to a 10b5-1 Trading Plan adopted by the Reporting Person, which is intended to comply with Rule 10b5-1. F2: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. Amount includes 354 shares acquired under the Issuer's employee stock purchase plan in April 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale effected pursuant to a 10b5-1 Trading Plan adopted by the Reporting Person, which is intended to comply with Rule 10b5-1.
F2: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. Amount includes 354 shares acquired under the Issuer's employee stock purchase plan in April 2020.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Sight Sciences, Inc.
Report date August 31, 2025 · Filed September 03, 2025
Section 16 reporting ended · disclosed 2025-09-03. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 23, 2026 Filed Jun 24, 2026 00:00 UTC | FibroBiologics, Inc. FBLG · Entity 7875 | GrantStock Option (Right to Buy) · Derivative | 30,803 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001493152-26-029849 · ownership.xml · derivative · entry 1 Link Matthew · CIK 0001565950 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,803 Underlying: Common Stock · 30,803 shares Expires 2036-06-22 F1 · derivative.exercise_date: The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting. Read SEC document |
| July 02, 2025 Filed Jul 8, 2025 01:24 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 4,889 | $4.10 | $20,035.12 |
DisclosureSEC source: 0000950170-25-094421 · ownership.xml · nonDerivative · entry 1 Link Matthew · CIK 0001565950 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 832,293 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| June 12, 2025 Filed Jun 12, 2025 23:26 UTC | FibroBiologics, Inc. FBLG · Entity 7875 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001641172-25-014939 · ownership.xml · derivative · entry 1 Link Matthew · CIK 0001565950 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2025-06-11 F1 · derivative.exercise_date: The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting. Read SEC document |
| May 16, 2025 Filed May 22, 2025 00:37 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 6,631 | $3.02 | $20,012.36 |
DisclosureSEC source: 0000950170-25-075986 · ownership.xml · nonDerivative · entry 1 Link Matthew · CIK 0001565950 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 837,182 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), that were acquired by the Reporting Person under the Sight Sciences, Inc. 2021 Employee Stock Purchase Plan ("2021 ESPP"). F2 · price: Reflects the price at which the shares were acquired under the 2021 ESPP, which is equal to 85% of the fair market value of the Common Stock on the last day of the offering period under the 2021 ESPP. Read SEC document |
| April 02, 2025 Filed Apr 4, 2025 01:56 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 5,042 | $2.31 | $11,641.98 |
DisclosureSEC source: 0000950170-25-050867 · ownership.xml · nonDerivative · entry 1 Link Matthew · CIK 0001565950 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 830,551 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| March 11, 2025 Filed Mar 14, 2025 01:52 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 172,043 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-039076 · ownership.xml · nonDerivative · entry 1 Link Matthew · CIK 0001565950 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 835,593 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's 2021 Incentive Award Plan. The RSUs vest in 16 equal quarterly installments commencing March 31, 2025 and continuing through December 31, 2028, subject to the Reporting Person's continued service to the Issuer through each vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to $480,000 divided by the closing price of the Common Stock on the grant date, which was March 11, 2025. The RSUs have no expiration date. Read SEC document |
| October 21, 2024 Filed Oct 22, 2024 01:46 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 21,831 | $5.61 | $122,450.08 |
DisclosureSEC source: 0000950170-24-116075 · ownership.xml · nonDerivative · entry 2 Link Matthew · CIK 0001565950 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 663,550 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. F3 · price: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $5.50 to $5.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 18, 2024 Filed Oct 22, 2024 01:46 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 20,487 | $5.98 | $122,450.80 |
DisclosureSEC source: 0000950170-24-116075 · ownership.xml · nonDerivative · entry 1 Link Matthew · CIK 0001565950 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 685,381 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. F2 · price: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $5.86 to $6.075, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 17, 2024 Filed Oct 18, 2024 23:43 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 20,970 | $5.84 | $122,443.83 |
DisclosureSEC source: 0000950170-24-115724 · ownership.xml · nonDerivative · entry 2 Link Matthew · CIK 0001565950 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 705,868 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 23:43 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 20,734 | $5.91 | $122,434.27 |
DisclosureSEC source: 0000950170-24-115724 · ownership.xml · nonDerivative · entry 1 Link Matthew · CIK 0001565950 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 726,838 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| August 27, 2024 Filed Aug 27, 2024 23:54 UTC | FibroBiologics, Inc. FBLG · Entity 7875 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0001493152-24-034070 · ownership.xml · derivative · entry 1 Link Matthew · CIK 0001565950 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2034-08-26 F1 · derivative.exercise_date: The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 23:49 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantStock Option (Right to Buy) · Derivative | 526,430 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0000950170-23-064604 · ownership.xml · derivative · entry 2 Link Matthew · CIK 0001565950 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 526,430 Underlying: Common Stock · 526,430 shares Expires 2033-11-14 F2 · shares: Reflects a grant of stock options ("Options") made to the Reporting Person under the 2021 Plan. The Options vest and become exercisable as to 25% of the underlying shares on September 11, 2024, and as to the remainder of such shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date, such that all such Options shall be fully vested and exercisable on September 11, 2027. F2 · derivative.exercise_date: Reflects a grant of stock options ("Options") made to the Reporting Person under the 2021 Plan. The Options vest and become exercisable as to 25% of the underlying shares on September 11, 2024, and as to the remainder of such shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date, such that all such Options shall be fully vested and exercisable on September 11, 2027. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 23:49 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 747,572 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-064604 · ownership.xml · nonDerivative · entry 1 Link Matthew · CIK 0001565950 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 747,572 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's 2021 Incentive Award Plan (the "2021 Plan"). The RSUs vest in four equal annual installments commencing October 15, 2024 and continuing through October 15, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share. The RSUs have no expiration date. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 17:52 UTC | NUVASIVE INC NUVA · Entity 110002 | SaleCommon Stock | 3,000 | $67.00 | $201,000.00 |
DisclosureSEC source: 0001209191-20-035649 · doc4.xml · nonDerivative · entry 1 Link Matthew · CIK 0001565950 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,595 F1 · shares: Sale effected pursuant to a 10b5-1 Trading Plan adopted by the Reporting Person, which is intended to comply with Rule 10b5-1. F2 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. Amount includes 354 shares acquired under the Issuer's employee stock purchase plan in April 2020. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 17:48 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantRSUs · Derivative | 12,190 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015516 · doc4.xml · derivative · entry 4 Link Matthew · CIK 0001565950 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,190 Underlying: Common Stock · 12,190 shares Expires not disclosed F5 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F6 · derivative.exercise_date: This RSU award was granted to the Reporting Person on March 2, 2020. In accordance with the terms of the RSU award, the award will vest in full on March 1, 2023. F6 · derivative.expiration_date: This RSU award was granted to the Reporting Person on March 2, 2020. In accordance with the terms of the RSU award, the award will vest in full on March 1, 2023. Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 17:48 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionPRSUs · Derivative | 7,929 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015516 · doc4.xml · derivative · entry 3 Link Matthew · CIK 0001565950 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,929 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Each Performance Restricted Stock Unit ("PRSU") represents the right to receive one share of the Issuer's common stock upon vesting. F4 · derivative.exercise_date: This PRSU award was granted to the Reporting Person on March 1, 2017. In accordance with the terms of the PRSU award, the award vested as to 7,929 shares on March 1, 2020. F4 · derivative.expiration_date: This PRSU award was granted to the Reporting Person on March 1, 2017. In accordance with the terms of the PRSU award, the award vested as to 7,929 shares on March 1, 2020. Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 17:48 UTC | NUVASIVE INC NUVA · Entity 110002 | Tax withholdingCommon Stock | 2,769 | $65.81 | $182,227.89 |
DisclosureSEC source: 0001209191-20-015516 · doc4.xml · nonDerivative · entry 2 Link Matthew · CIK 0001565950 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,241 F2 · shares: Shares withheld by the Issuer to satisfy tax withholding obligations. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 17:48 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionCommon Stock | 7,929 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015516 · doc4.xml · nonDerivative · entry 1 Link Matthew · CIK 0001565950 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,010 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Read SEC document |
| January 16, 2020 Filed Jan 17, 2020 17:53 UTC | NUVASIVE INC NUVA · Entity 110002 | SaleCommon Stock | 3,000 | $79.80 | $239,400.00 |
DisclosureSEC source: 0001209191-20-004138 · doc4.xml · nonDerivative · entry 1 Link Matthew · CIK 0001565950 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,081 F1 · shares: Sale effected pursuant to a 10b5-1 Trading Plan adopted by the Reporting Person, which is intended to comply with Rule 10b5-1. F2 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. Read SEC document |
| December 24, 2019 Filed Dec 27, 2019 17:49 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 260 | $0.00 Strike: $26.62 | $0.00 |
DisclosureSEC source: 0001209191-19-062039 · doc4.xml · derivative · entry 7 Link Matthew · CIK 0001565950 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 260 shares Expires 2021-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: These stock options, representing a right to purchase a total of 260 shares, were granted on January 3, 2011 and are fully vested. Read SEC document |
| December 24, 2019 Filed Dec 27, 2019 17:49 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $44.24 | $0.00 |
DisclosureSEC source: 0001209191-19-062039 · doc4.xml · derivative · entry 6 Link Matthew · CIK 0001565950 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2020-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: These stock options, representing a right to purchase a total of 12,500 shares, were granted on April 1, 2010 and are fully vested. Read SEC document |
| December 24, 2019 Filed Dec 27, 2019 17:49 UTC | NUVASIVE INC NUVA · Entity 110002 | Tax withholdingCommon Stock | 8,672 | $77.70 | $673,814.40 |
DisclosureSEC source: 0001209191-19-062039 · doc4.xml · nonDerivative · entry 5 Link Matthew · CIK 0001565950 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,081 F5 · shares: Payment of exercise price and tax liability by Issuer's withholding of shares incident to the respective option exercise. F2 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. Read SEC document |
| December 24, 2019 Filed Dec 27, 2019 17:49 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionCommon Stock | 260 | $26.62 | $6,921.20 |
DisclosureSEC source: 0001209191-19-062039 · doc4.xml · nonDerivative · entry 4 Link Matthew · CIK 0001565950 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. Read SEC document |
| December 24, 2019 Filed Dec 27, 2019 17:49 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionCommon Stock | 12,500 | $44.24 | $553,000.00 |
DisclosureSEC source: 0001209191-19-062039 · doc4.xml · nonDerivative · entry 3 Link Matthew · CIK 0001565950 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,448 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. Read SEC document |
| December 24, 2019 Filed Dec 27, 2019 17:49 UTC | NUVASIVE INC NUVA · Entity 110002 | SaleCommon Stock | 3,500 | $77.38 | $270,830.00 |
DisclosureSEC source: 0001209191-19-062039 · doc4.xml · nonDerivative · entry 2 Link Matthew · CIK 0001565950 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,948 F3 · shares: Sales effected pursuant to a 10b5-1 Trading Plan adopted by the Reporting Person, which is intended to comply with Rule 10b5-1. F4 · price: Weighted average sales price from sales transactions ranging from $77.15 to $77.61. Upon request by the Commission staff, the Issuer or a security holder of the Issuer, the Reporting Person will undertake to provide full information regarding the number of shares sold at each separate price. F2 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. Read SEC document |
| November 20, 2019 Filed Dec 27, 2019 17:49 UTC | NUVASIVE INC NUVA · Entity 110002 | GiftCommon Stock | 695 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-062039 · doc4.xml · nonDerivative · entry 1 Link Matthew · CIK 0001565950 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,448 F1 · shares: Represents a gift of 695 shares. F2 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. Read SEC document |
| May 02, 2019 Filed May 6, 2019 17:55 UTC | NUVASIVE INC NUVA · Entity 110002 | SaleCommon Stock | 10,100 | $62.00 | $626,200.00 |
DisclosureSEC source: 0001209191-19-027822 · doc4.xml · nonDerivative · entry 1 Link Matthew · CIK 0001565950 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,143 F1 · shares: Sales effected pursuant to a 10b5-1 Trading Plan adopted by the Reporting Person, which is intended to comply with Rule 10b5-1. F2 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. Amount includes 436 shares acquired under the Issuer's employee stock purchase plan in April 2019. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 17:48 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantRSUs · Derivative | 12,825 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-016829 · doc4.xml · derivative · entry 5 Link Matthew · CIK 0001565950 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,825 Underlying: Common Stock · 12,825 shares Expires not disclosed F6 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F7 · derivative.exercise_date: This RSU award was granted to the Reporting Person on March 1, 2019. In accordance with the terms of the RSU award, the award will vest in full on March 1, 2022. F7 · derivative.expiration_date: This RSU award was granted to the Reporting Person on March 1, 2019. In accordance with the terms of the RSU award, the award will vest in full on March 1, 2022. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 17:48 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionPRSUs · Derivative | 14,403 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-016829 · doc4.xml · derivative · entry 4 Link Matthew · CIK 0001565950 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,403 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Each Performance Restricted Stock Unit ("PRSU") represents the right to receive one share of the Issuer's common stock upon vesting. F5 · derivative.exercise_date: This PRSU award was granted to the Reporting Person on March 1, 2016. In accordance with the terms of the PRSU award, the award vested as to 14,403 shares on March 1, 2019. F5 · derivative.expiration_date: This PRSU award was granted to the Reporting Person on March 1, 2016. In accordance with the terms of the PRSU award, the award vested as to 14,403 shares on March 1, 2019. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 17:48 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionPRSUs · Derivative | 4,754 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-016829 · doc4.xml · derivative · entry 3 Link Matthew · CIK 0001565950 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,754 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Each Performance Restricted Stock Unit ("PRSU") represents the right to receive one share of the Issuer's common stock upon vesting. F4 · derivative.exercise_date: This PRSU award was granted to the Reporting Person on March 1, 2016. In accordance with the terms of the PRSU award, the award vested as to 4,754 shares on March 1, 2019. F4 · derivative.expiration_date: This PRSU award was granted to the Reporting Person on March 1, 2016. In accordance with the terms of the PRSU award, the award vested as to 4,754 shares on March 1, 2019. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 17:48 UTC | NUVASIVE INC NUVA · Entity 110002 | Tax withholdingCommon Stock | 7,267 | $58.48 | $424,974.16 |
DisclosureSEC source: 0001209191-19-016829 · doc4.xml · nonDerivative · entry 2 Link Matthew · CIK 0001565950 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,807 F2 · shares: Shares withheld by the Issuer to satisfy tax withholding obligations. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 17:48 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionCommon Stock | 19,157 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-016829 · doc4.xml · nonDerivative · entry 1 Link Matthew · CIK 0001565950 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Read SEC document |
| February 06, 2019 Filed Feb 7, 2019 17:42 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantPRSUs · Derivative | 4,754 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008178 · doc4.xml · derivative · entry 2 Link Matthew · CIK 0001565950 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,754 Underlying: Common Stock · 4,754 shares Expires not disclosed F1 · security: Each Performance Restricted Stock Unit ("PRSU") represents the right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: This PRSU award was granted to the Reporting Person on March 1, 2016. The award was granted based on a target number of shares with a performance multiplier of 0-250% based on the Issuer's total stockholder return over the performance period ended December 31, 2018. On February 6, 2019, the Compensation Committee of the Issuer's Board of Directors certified the Issuer's performance for purposes of the award. Based on the Issuer's performance, the award will vest as to 4,754 shares on March 1, 2019, subject to and in accordance with the terms of the award. As the award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time of grant. F3 · derivative.expiration_date: This PRSU award was granted to the Reporting Person on March 1, 2016. The award was granted based on a target number of shares with a performance multiplier of 0-250% based on the Issuer's total stockholder return over the performance period ended December 31, 2018. On February 6, 2019, the Compensation Committee of the Issuer's Board of Directors certified the Issuer's performance for purposes of the award. Based on the Issuer's performance, the award will vest as to 4,754 shares on March 1, 2019, subject to and in accordance with the terms of the award. As the award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time of grant. Read SEC document |
| February 06, 2019 Filed Feb 7, 2019 17:42 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantPRSUs · Derivative | 11,277 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008178 · doc4.xml · derivative · entry 1 Link Matthew · CIK 0001565950 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,277 Underlying: Common Stock · 11,277 shares Expires not disclosed F1 · security: Each Performance Restricted Stock Unit ("PRSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: This PRSU award was granted to the Reporting Person on April 30, 2018. The award was granted with a performance condition based on the Issuer's earnings per share over the performance period ended December 31, 2018. On February 6, 2019, the Compensation Committee of the Issuer's Board of Directors certified the Issuer's performance for purposes of the award. Based on the Issuer's performance, the award will vest as to 11,277 shares on April 30, 2021, subject to and in accordance with the terms of the award. As the award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time of grant. F2 · derivative.expiration_date: This PRSU award was granted to the Reporting Person on April 30, 2018. The award was granted with a performance condition based on the Issuer's earnings per share over the performance period ended December 31, 2018. On February 6, 2019, the Compensation Committee of the Issuer's Board of Directors certified the Issuer's performance for purposes of the award. Based on the Issuer's performance, the award will vest as to 11,277 shares on April 30, 2021, subject to and in accordance with the terms of the award. As the award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time of grant. Read SEC document |
| February 01, 2019 Filed Feb 4, 2019 18:00 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionPRSUs · Derivative | 2,660 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-006918 · doc4.xml · derivative · entry 3 Link Matthew · CIK 0001565950 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,660 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Each Performance Restricted Stock Unit ("PRSU") represents the right to receive one share of the Issuer's common stock upon vesting. F4 · derivative.exercise_date: This PRSU award was granted to the Reporting Person on February 17, 2015. In accordance with the terms of the PRSU award, the award vested as to 2,661 shares on February 1, 2016, and vested as to 2,660 shares on each of February 1, 2017, February 1, 2018 and February 1, 2019. F4 · derivative.expiration_date: This PRSU award was granted to the Reporting Person on February 17, 2015. In accordance with the terms of the PRSU award, the award vested as to 2,661 shares on February 1, 2016, and vested as to 2,660 shares on each of February 1, 2017, February 1, 2018 and February 1, 2019. Read SEC document |
| February 01, 2019 Filed Feb 4, 2019 18:00 UTC | NUVASIVE INC NUVA · Entity 110002 | Tax withholdingCommon Stock | 1,032 | $49.13 | $50,702.16 |
DisclosureSEC source: 0001209191-19-006918 · doc4.xml · nonDerivative · entry 2 Link Matthew · CIK 0001565950 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,917 F2 · shares: Shares withheld by the Issuer to satisfy tax withholding obligations. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Read SEC document |
| February 01, 2019 Filed Feb 4, 2019 18:00 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionCommon Stock | 2,660 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-006918 · doc4.xml · nonDerivative · entry 1 Link Matthew · CIK 0001565950 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,949 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 17:55 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 500 | $0.00 Strike: $34.82 | $0.00 |
DisclosureSEC source: 0001209191-18-063551 · doc4.xml · derivative · entry 3 Link Matthew · CIK 0001565950 · President, Strat/Tech/Corp Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing a right to purchase a total of 500 shares, was granted on January 2, 2009 and is fully vested. F3 · derivative.expiration_date: The option, representing a right to purchase a total of 500 shares, was granted on January 2, 2009 and is fully vested. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 17:55 UTC | NUVASIVE INC NUVA · Entity 110002 | Tax withholdingCommon Stock | 327 | $53.15 | $17,380.05 |
DisclosureSEC source: 0001209191-18-063551 · doc4.xml · nonDerivative · entry 2 Link Matthew · CIK 0001565950 · President, Strat/Tech/Corp Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,289 F2 · shares: Payment of exercise price by Issuer's withholding of shares incident to the respective option exercise. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 17:55 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionCommon Stock | 500 | $34.82 | $17,410.00 |
DisclosureSEC source: 0001209191-18-063551 · doc4.xml · nonDerivative · entry 1 Link Matthew · CIK 0001565950 · President, Strat/Tech/Corp Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,616 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Read SEC document |
| December 03, 2018 Filed Dec 4, 2018 18:06 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantRSUs · Derivative | 20,065 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-061019 · doc4.xml · derivative · entry 1 Link Matthew · CIK 0001565950 · President, Strat/Tech/Corp Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,065 Underlying: Common Stock · 20,065 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: This RSU award was granted to the Reporting Person on December 3, 2018. In accordance with the terms of the RSU award, the award will vest in full on December 3, 2021. F2 · derivative.expiration_date: This RSU award was granted to the Reporting Person on December 3, 2018. In accordance with the terms of the RSU award, the award will vest in full on December 3, 2021. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 17:57 UTC | NUVASIVE INC NUVA · Entity 110002 | SaleCommon Stock | 4,889 | $62.22 | $304,193.58 |
DisclosureSEC source: 0001209191-18-059955 · doc4.xml · nonDerivative · entry 1 Link Matthew · CIK 0001565950 · President, Strat/Tech/Corp Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,116 F1 · shares: Sales effected pursuant to a 10b5-1 Trading Plan adopted by the Reporting Person, which is intended to comply with Rule 10b5-1. F2 · price: Weighted average sales price from sales transactions ranging from $62.00 to $62.54. Upon request by the Commission staff, the Issuer or a security holder of the Issuer, the Reporting Person will undertake to provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. Read SEC document |
| November 19, 2018 Filed Nov 20, 2018 17:56 UTC | NUVASIVE INC NUVA · Entity 110002 | SaleCommon Stock | 1,382 | $62.02 | $85,711.64 |
DisclosureSEC source: 0001209191-18-059508 · doc4.xml · nonDerivative · entry 2 Link Matthew · CIK 0001565950 · President, Strat/Tech/Corp Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,005 F1 · shares: Sales effected pursuant to a 10b5-1 Trading Plan adopted by the Reporting Person, which is intended to comply with Rule 10b5-1. F4 · price: Weighted average sales price from sales transactions ranging from $62.00 to $62.07. Upon request by the Commission staff, the Issuer or a security holder of the Issuer, the Reporting Person will undertake to provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. Amount includes 444 shares acquired under the Issuer's employee stock purchase plan in April 2018. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 17:56 UTC | NUVASIVE INC NUVA · Entity 110002 | SaleCommon Stock | 1,200 | $62.01 | $74,412.00 |
DisclosureSEC source: 0001209191-18-059508 · doc4.xml · nonDerivative · entry 1 Link Matthew · CIK 0001565950 · President, Strat/Tech/Corp Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,387 F1 · shares: Sales effected pursuant to a 10b5-1 Trading Plan adopted by the Reporting Person, which is intended to comply with Rule 10b5-1. F2 · price: Weighted average sales price from sales transactions ranging from $62.00 to $62.06. Upon request by the Commission staff, the Issuer or a security holder of the Issuer, the Reporting Person will undertake to provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. Amount includes 444 shares acquired under the Issuer's employee stock purchase plan in April 2018. Read SEC document |
| February 07, 2018 Filed Feb 7, 2019 17:41 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantPRSUs · Derivative | 7,929 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008174 · doc5.xml · derivative · entry 1 Link Matthew · CIK 0001565950 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,929 Underlying: Common Stock · 7,929 shares Expires not disclosed F1 · security: Each Performance Restricted Stock Unit ("PRSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: This PRSU award was granted to the Reporting Person on March 1, 2017. The award was granted with a performance condition based on the Issuer's earnings per share over the performance period ended December 31, 2017. On February 7, 2018, the Compensation Committee of the Issuer's Board of Directors certified the Issuer's performance for purposes of the award. Based on the Issuer's performance, the award will vest as to 7,929 shares on March 1, 2020, subject to and in accordance with the terms of the award. As the award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time of grant. Due to an administrative error, a Form 4 reporting the certification of the performance condition was not filed in February 2018. F2 · derivative.expiration_date: This PRSU award was granted to the Reporting Person on March 1, 2017. The award was granted with a performance condition based on the Issuer's earnings per share over the performance period ended December 31, 2017. On February 7, 2018, the Compensation Committee of the Issuer's Board of Directors certified the Issuer's performance for purposes of the award. Based on the Issuer's performance, the award will vest as to 7,929 shares on March 1, 2020, subject to and in accordance with the terms of the award. As the award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time of grant. Due to an administrative error, a Form 4 reporting the certification of the performance condition was not filed in February 2018. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 17:55 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionPRSUs · Derivative | 2,660 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-007629 · doc4.xml · derivative · entry 3 Link Matthew · CIK 0001565950 · EVP, Strategy, Tech & Corp Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,660 Underlying: Common Stock · 2,660 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Each Performance Restricted Stock Unit ("PRSU") represents the right to receive one share of the Issuer's common stock upon vesting. F4 · derivative.exercise_date: This PRSU award was granted to the Reporting Person on February 17, 2015. In accordance with the terms of the PRSU award, the award vested as to 2,661 shares on February 1, 2016, vested as to 2,660 shares on February 1, 2017 and February 1, 2018 and will vest as to 2,660 shares on February 1, 2019. F4 · derivative.expiration_date: This PRSU award was granted to the Reporting Person on February 17, 2015. In accordance with the terms of the PRSU award, the award vested as to 2,661 shares on February 1, 2016, vested as to 2,660 shares on February 1, 2017 and February 1, 2018 and will vest as to 2,660 shares on February 1, 2019. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 17:55 UTC | NUVASIVE INC NUVA · Entity 110002 | Tax withholdingCommon Stock | 1,027 | $48.50 | $49,809.50 |
DisclosureSEC source: 0001209191-18-007629 · doc4.xml · nonDerivative · entry 2 Link Matthew · CIK 0001565950 · EVP, Strategy, Tech & Corp Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,143 F2 · shares: Shares withheld by the Issuer to satisfy tax withholding obligations. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 17:55 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionCommon Stock | 2,660 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-007629 · doc4.xml · nonDerivative · entry 1 Link Matthew · CIK 0001565950 · EVP, Strategy, Tech & Corp Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,170 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Read SEC document |
| December 27, 2017 Filed Dec 29, 2017 17:57 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,150 | $0.00 Strike: $38.78 | $0.00 |
DisclosureSEC source: 0001209191-17-067668 · doc4.xml · derivative · entry 5 Link Matthew · CIK 0001565950 · EVP, Strategy, Tech & Corp Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,150 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing a right to purchase a total of 2,150 shares, was granted on January 2, 2008 and is fully vested. F4 · derivative.expiration_date: The option, representing a right to purchase a total of 2,150 shares, was granted on January 2, 2008 and is fully vested. Read SEC document |
| December 27, 2017 Filed Dec 29, 2017 17:57 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,350 | $0.00 Strike: $38.78 | $0.00 |
DisclosureSEC source: 0001209191-17-067668 · doc4.xml · derivative · entry 4 Link Matthew · CIK 0001565950 · EVP, Strategy, Tech & Corp Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,350 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing a right to purchase a total of 5,350 shares, was granted on January 2, 2008 and is fully vested. F3 · derivative.expiration_date: The option, representing a right to purchase a total of 5,350 shares, was granted on January 2, 2008 and is fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.